Composition, form of production and packaging
? Cream rectal homogeneous, white, with a weak characteristic odor.
100 g
tribenoside 5 g
lidocaine hydrochloride 2.12 g
Auxiliary substances: cetomacrogol 1000-4.44 g, cetyl alcohol 5 g, isopropyl palmitate 2 g, paraffin liquid 10 g, methyl parahydroxybenzoate 0.18 g, propyl parahydroxybenzoate 0.05 g, sorbitan stearate 1.56 g, sorbitol 6 g, stearic acid - 9 g, water - 54.65 g.
30 grams - tubes of aluminum (1) complete with a polyethylene tip and a capping cap made of latex - packs of cardboard.
INSTRUCTION FOR THE SPECIALIST.
Description of the drug approved by the manufacturer for the printed edition of 2016.
PHARMACHOLOGIC EFFECT
Combined antihemorrhoidal drug.
Tribenozid reduces the permeability of capillaries and improves vascular tone, antagonistically affects some endogenous substances that act as mediators in the development of inflammation and pain.
Lidocaine has a local anesthetic effect.
The drug causes a rapid weakening of symptoms caused by hemorrhoids (pain, itching and skin tension).
PHARMACOKINETICS
Suction
When topical application is absorbed from 2 to 20% of the tribenozide contained in the cream.
Metabolism
In the body, tribenozide is largely metabolized in the liver.
INDICATIONS
- external and internal hemorrhoids.
DOSING MODE
Rectally.
With severe clinical symptoms, the cream should be applied morning and evening.
When regression of acute symptoms, the frequency of application is reduced to 1 time / day.
With internal hemorrhoids, the cream is injected with a nozzle. 30 g of cream (1 tube) is sufficient for approximately 20-30 applications.
SIDE EFFECT
On the part of the immune system: very rarely (<1/10 000) - anaphylactic reactions, including angioedema, facial edema, bronchospasm and cardiovascular disorders.
From the skin and subcutaneous tissues: rarely (> 1/10 000, <1/1 000) - skin reactions at the site of application (burning, rash, itching and urticaria). These symptoms can spread beyond the site of application.
CONTRAINDICATIONS
- hypersensitivity to the components of the drug;
- liver failure;
- I trimester of pregnancy.
PREGNANCY AND LACTATION
Application in the first trimester of pregnancy is contraindicated. When using the drug in the II and III trimesters of pregnancy, it is necessary to take into account the possible risk to the fetus.
If you need to use the drug during breastfeeding, you should weigh the expected benefit of therapy for the mother and the potential risk to the child.
APPLICATION FOR VIOLATIONS OF THE FUNCTION OF KIDNEYS
Contraindicated in liver failure.
SPECIAL INSTRUCTIONS
If the symptoms of the disease do not subside during treatment or if new unusual sensations appear, you should consult your doctor.
When applying Procto-Glivenol В® cream, it is necessary to monitor the hygiene of the anal area, avoid excessive stress, take measures to maintain a soft stool consistency.
Impact on the ability to drive vehicles and mechanisms
The drug does not affect the concentration of attention and rapidity of mental and motor reactions when used in recommended doses.
OVERDOSE
Cases of drug overdose are not registered.
Treatment: In case of accidental ingestion, gastrointestinal rinsing is recommended, as well as symptomatic maintenance therapy.
DRUG INTERACTION
The cases of interaction are not registered.
TERMS OF RELEASE FROM PHARMACY
Without recipe.
TERMS AND CONDITIONS OF STORAGE
The drug should be stored at a temperature of no higher than 30 В° C. Shelf life - 5 years. Do not use after the expiration date.
Keep out of the reach of children.